Inflectra(TM) (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease (y 3)

References

1. Gecse K, et al. Biosimilar infliximab in inflammatory bowel disease: first interim results from a prospective nationwide observational cohort.
Abstract P314. Presented February 2015 at ECCO-ibd, Barcelona, Spain.

2. Kim J, et al. 5 year budget impact analysis of CT-P13 (infliximab) for the treatment of Crohn's disease in UK, Italy and France. Abstract P137.
Presented February 2015 at ECCO-ibd, Barcelona, Spain.

3. The European Federation of Crohn's and Ulcerative Colitis Associations. What is IBD? Available at: http://www.efcca.org/index.php/about-efcca/
what-are-ibd. Last accessed February 2015.

4. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014. Jan;
73(1): 198-206.

5. Weise M. et al. Biosimilars: what clinicians should know. Blood. 2012; 120: 5111-5117.

6. Danese S, Colombel J, Reinisch W et al. Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of
clinical experience. Alimentary Pharmacology and Therapeutics. 2011; 33: 857-869.

7. EMA. Inflectra European Public Assessment Report - Summary for the public. EMA/402688/2013. Available at http://www.ema.europa.eu/ema/
index.jsp?curl=/pages/medicines/human/medicines/002778/human_med_001677.jsp. Last accessed January 2015.

8. Inflectra (infliximab). Summary of Product Characteristics. 2014.

CONTACT: European Media, Jenny Squibbs, 90TEN Healthcare,+44-20-7627-0990, U.S. Media, Ann Fahey-Widman, Hospira, +1-224-212-3294,Financial Community, Karen King, Hospira, +1-224-212-2711, Ruth Venning,Hospira, +1-224-212-2711

Web site: http://www.hospira.com/